# BPC-157 — Research Peptide Profile

> One of few orally stable peptides, with 100+ preclinical studies across tendon, gut and wound repair. Mechanism, 15-min half-life, research dosing & cited studies.

Source: https://peptpedia.org/peptide/bpc-157 | Published: 2025-12-02 | Last updated: 2026-07-22

BPC-157 is a synthetic 15-amino-acid peptide derived from a protective protein in human gastric juice. It is one of the most-studied regenerative peptides in preclinical research, with documented effects across tendon, muscle, gut, and bone — though every completed study is in animals or cell models. Its stability in gastric acid also makes it orally active, a rarity among peptides.

## Overview

BPC-157 is a synthetic 15-amino acid peptide (C₆₂H₉₈N₁₆O₂₂; CAS 137525-51-0) derived from a protective protein found in human gastric juice. First characterized by Sikiric et al. in the early 1990s, it is notable for [stability in gastric acid](/research/bpc-157-stability), enabling rare oral bioavailability among research peptides. Over 100 preclinical studies document tissue repair, gastrointestinal protection, wound healing, and neuroprotective effects. All current evidence is from animal or in vitro models; no completed human clinical trials have been published.

## Molecular Profile

- **Category:** recovery-repair
- **Molecular formula:** C62H98N16O22
- **Molecular weight:** 1419.53 g/mol
- **CAS number:** 137525-51-0
- **Amino acid sequence:** Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
- **Also known as:** Body Protection Compound-157, Pentadecapeptide BPC 157
- **Half-life:** 15.2 minutes (rat, IV); tissue effects persist for weeks despite rapid clearance
- **Solubility:** Water soluble; bacteriostatic water recommended
- **Storage:** Store lyophilized powder at -20°C. Reconstituted solution stable at 4°C for limited time.

## Mechanism of Action

BPC-157 is believed to work through multiple mechanisms, including upregulation of growth hormone receptors, modulation of nitric oxide synthesis, and interaction with the dopaminergic system. Research suggests it may promote [angiogenesis](/research/bpc-157-angiogenesis) (formation of new blood vessels) and accelerate the healing cascade. Studies indicate potential involvement with the FAK-paxillin pathway, which plays a role in cell adhesion and tissue repair. Additionally, BPC-157 may interact with the nitric oxide system to promote vascular function and tissue regeneration.

## Key Research Findings

- BPC-157 is cleared from circulation in approximately 15 minutes, yet its tissue repair signals persist for weeks, suggesting a hit-and-run pharmacological mechanism.
- BPC-157 is one of very few peptides that remains stable in human gastric juice, giving it meaningful oral bioavailability in preclinical models.
- BPC-157 promotes organized blood vessel formation through the Egr-1/NAB2 pathway, which acts as both an accelerator and a brake to prevent aberrant vessel growth.
- Over 100 published preclinical studies have demonstrated protective and reparative effects of BPC-157 across tendon, muscle, bone, and gastrointestinal tissue.

## The Pharmacokinetic Precision Gap

Researchers often cite estimated metabolic rates for BPC-157, but precise preclinical data provides a more nuanced understanding of its therapeutic behavior. Understanding the interplay between its rapid clearance and its prolonged biological effect is essential for interpreting its unique research applications.

### Systemic Half-Life: The 15.2-Minute Reality

Formal pharmacokinetic studies have established that BPC-157 is cleared from systemic circulation with remarkable speed.

- Mean Elimination Half-Life (t½): In rats, the average elimination half-life after a single intravenous (IV) administration is 15.2 minutes.
- Prototype Clearance: The prototype drug typically becomes undetectable in plasma within 4 hours post-administration.
- Metabolic Fate: BPC-157 is primarily metabolized in the liver, where it is broken down into smaller peptide fragments and individual amino acids that enter normal metabolic pathways.

### The Gene Expression Paradox

Despite a systemic presence measured in minutes, BPC-157 exerts regenerative effects that persist for weeks. This is often described as the Gene Expression Paradox, a phenomenon where a short-lived peptide initiates a permanent healing cascade.

- Rapid Gene Activation: Within the first hour of administration, BPC-157 triggers a significant burst of gene expression.
- Tendon-Specific Upregulation: Microarray analysis reveals that BPC-157 significantly increases the expression of the Growth Hormone Receptor (GHR) in tendon fibroblasts.
- Biological Durability: The peptide's immediate interaction with transcription factors like c-Fos, c-Jun, and Egr-1 allows for angiogenic and anti-inflammatory processes that far outlast the physical presence of the molecule.

## The Precision of BPC-157 Angiogenesis

While many compounds can force the growth of new blood vessels (angiogenesis), they often do so in a disorganized way that can lead to leaky vessels or unwanted tissue growth. BPC-157 is distinguished in research for its ability to promote organized, stable vessel formation through a series of molecular safety checks.

### The Master Switch and the Brake (Egr-1 / NAB2 Loop)

In preclinical models, BPC-157 doesn't just push the on switch for healing; it manages the entire process like a thermostat.

- The Master Switch: It rapidly activates a gene called Egr-1, which acts as a master controller to start building the proteins and vessels needed to close a wound.
- The Internal Brake: Simultaneously, BPC-157 triggers NAB2, a natural protein that acts as a brake on Egr-1.
- Organized Repair: By turning on both the switch and the brake at the same time, BPC-157 ensures the body produces enough new vessels to repair the injury without allowing the chaotic, excessive growth often seen in chronic inflammation or tumor environments.

### Maintaining Vascular Balance (The NO System)

Beyond direct growth, BPC-157 acts as a sophisticated moderator for Nitric Oxide (NO), the gas the body uses to relax blood vessels and direct blood flow to an injury.

- Unlocking the System: In its resting state, the enzyme that produces nitric oxide is often locked and inactive. BPC-157 triggers a specific chemical signal (Src-Caveolin-1 phosphorylation) that unlocks this enzyme, allowing a controlled release of nitric oxide to start the healing process.
- Homeostatic Control: Because this works on a regulatory level, BPC-157 is modulatory. This means it can help the body if there is too little nitric oxide, but it also has the potential to step in if levels become dangerously high. This balancing act helps maintain vascular stability and prevents the system-wide collapse that can occur when nitric oxide levels are out of sync.

This controlled approach to angiogenesis is why BPC-157 is often studied in sensitive areas like the eye or the gut. For example, while other growth factors might cause cloudy vision by growing vessels where they don't belong, research shows BPC-157 can promote healing in the eye while actively maintaining corneal transparency by opposing pathological vessel growth.

## Safety & Tolerability

Across preclinical research, BPC-157 has been reported to have a favorable tolerability profile: a 2021 Frontiers in Pharmacology review noted no reported toxicity in animal studies, with the LD1 (lethal dose for 1% of animals) not reached. All quantitative safety findings derive from animal and in-vitro models; controlled human safety data is limited and incomplete.

**Human data status:** Human exposure is limited and largely unpublished. BPC-157 (as PL-14736) was evaluated in early human inflammatory-bowel-disease/ulcerative-colitis trials and reportedly in multiple-sclerosis trials; these were not completed in peer-reviewed form, and a Phase I safety study has been mentioned in the literature but its results were never published. No completed, peer-reviewed human efficacy or long-term safety trial exists as of 2026.

**Regulatory status:** Not approved by the FDA (or any regulatory agency) for human use. Prohibited in sport under the WADA Prohibited List, category S0 (Non-Approved Substances).

- A 2021 review reported no toxicity in BPC-157 animal studies, with the LD1 not achieved, and noted prior use in ulcerative colitis and multiple sclerosis trials. (evidence tier: animal; [PMID 34267654](https://pubmed.ncbi.nlm.nih.gov/34267654/))
- Early human IBD/ulcerative-colitis trials of BPC-157 (PL-14736) reported it as safe with no reported toxicity — but these clinical trials were not completed or fully published. (evidence tier: human-interventional; [PMID 21548867](https://pubmed.ncbi.nlm.nih.gov/21548867/))
- BPC-157 was formally evaluated "in trials for inflammatory bowel disease" (PL-10, PLD-116, PL-14736; Pliva, Croatia), documenting an early human development program that was not carried to completion. (evidence tier: human-interventional; [PMID 17186181](https://pubmed.ncbi.nlm.nih.gov/17186181/))

## Dosing Information (Research Context)

In published research studies, BPC-157 has been administered at various dosages depending on the research model. Animal studies have typically used doses ranging from 10 mcg/kg to 10 mg/kg body weight. Administration routes in research include subcutaneous, intramuscular, intraperitoneal, and oral. Researchers should consult original study protocols for specific experimental conditions.

| Route | Dose | Frequency | Notes |
| --- | --- | --- | --- |
| Subcutaneous | 10–20 mcg/kg | Once daily | Most common route in rodent studies |
| Intramuscular | 10–20 mcg/kg | Once daily | Used in musculoskeletal repair models |
| Intraperitoneal | 10 mcg/kg – 10 mg/kg | Varies by protocol | Wide range across published studies |
| Oral (gavage) | 10 mcg/kg – 10 mg/kg | Once daily | Exploits unique gastric stability |
| Intravenous | 10 mcg/kg | Single dose (PK studies) | Mean t½ 15.2 min in rats |

## Researched Effects

- **Tissue Repair & Regeneration** (evidence: extensive): Preclinical studies have demonstrated remarkable acceleration of healing across multiple tissue types including skeletal muscle tears, tendon injuries, ligament damage, and bone fractures. Research published in peer-reviewed journals shows BPC-157 enhances collagen synthesis and promotes proper tissue remodeling through upregulation of growth hormone receptors in fibroblasts. Studies in animal models have documented faster recovery from muscle crush injuries, Achilles tendon transection, and medial collateral ligament damage. The peptide appears to promote formation of granulation tissue and accelerate the transition from inflammatory to proliferative healing phases. Research indicates potential applications in sports medicine research for studying muscle strain recovery, rotator cuff repair mechanisms, and connective tissue regeneration pathways.
- **Gastrointestinal Protection** (evidence: extensive): Extensive research demonstrates powerful cytoprotective properties throughout the gastrointestinal tract, with studies showing protection against NSAID-induced gastric lesions, alcohol-induced stomach damage, and stress ulcers. BPC-157 has been investigated for inflammatory bowel disease mechanisms including ulcerative colitis and Crohn's disease models, showing reduced mucosal inflammation and accelerated intestinal healing. Research indicates the peptide may protect against esophageal damage, promote healing of intestinal anastomoses after surgery, and reduce liver damage from various toxins. Studies have documented effects on the gut-brain axis and potential benefits for intestinal permeability issues often referred to as leaky gut syndrome. The peptide's remarkable stability in gastric juice allows for oral administration in research settings, making it unique among therapeutic peptides.
- **Anti-inflammatory Activity** (evidence: moderate): Research demonstrates significant modulation of inflammatory pathways including reduction of pro-inflammatory cytokines such as TNF-alpha, IL-1 beta, and IL-6 in multiple tissue models. BPC-157 appears to counteract oxidative stress damage through enhancement of antioxidant enzyme systems and reduction of reactive oxygen species in damaged tissues. Studies show the peptide may reduce inflammation associated with adjuvant-induced arthritis, periodontitis, and various autoimmune condition models. The anti-inflammatory effects appear synergistic with tissue healing properties, creating an optimal environment for regeneration. Research indicates potential applications in studying chronic inflammatory conditions, post-surgical inflammation reduction, and inflammation-related pain mechanisms.
- **Wound Healing Acceleration** (evidence: extensive): Multiple controlled studies demonstrate significantly enhanced wound closure rates, with research showing up to 2-3 times faster healing in various wound models compared to controls. BPC-157 promotes robust granulation tissue formation, accelerated re-epithelialization, and improved tensile strength of healing wounds. Studies document enhanced angiogenesis with increased blood vessel formation in wound beds, providing better oxygen and nutrient delivery to healing tissues. Research in burn wound models, diabetic wound models, and surgical incision healing shows consistent acceleration of all phases of wound repair. The peptide has been studied for potential applications in chronic wound management studies, skin graft survival enhancement, and post-operative incision healing optimization.
- **Neuroprotective Effects** (evidence: preliminary): Preliminary research indicates significant protective effects on neural tissue including protection against chemotherapy-induced peripheral neuropathy and traumatic brain injury models. Studies suggest BPC-157 may promote peripheral nerve regeneration after crush injuries, with documented improvements in nerve fiber density and functional recovery. Research in dopaminergic system models shows potential relevance to Parkinson's disease mechanisms, with studies documenting protection against MPTP and other neurotoxic agents. The peptide appears to interact with nitric oxide pathways in the central nervous system, potentially influencing neurotransmitter balance and synaptic function. Emerging research explores applications in spinal cord injury repair, stroke recovery mechanisms, and protection against neurodegenerative processes.
- **Organoprotection** (evidence: moderate): Research demonstrates significant protective effects across multiple organ systems in preclinical models. Cardiac studies show elimination of arrhythmias in rat models and protection against ischemia-reperfusion injury. Hepatoprotective effects include reduced liver damage from alcohol and various toxins. Renal protection has been observed in models of acute kidney injury, with improved function markers and reduced tissue damage. Pulmonary studies indicate protection against lung injury models. The peptide appears to maintain organ function under stress conditions through nitric oxide system modulation and vascular protection mechanisms.

## Research Applications

- Tissue Engineering
- Wound Healing
- Gastroenterology
- Sports Medicine Research
- Neuroscience

## Key Studies

### Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease

Sikiric P, Seiwerth S, et al. — *Inflammopharmacology* (2006) — [PMID 17186181](https://pubmed.ncbi.nlm.nih.gov/17186181/) | [doi:10.1007/s10787-006-1531-7](https://doi.org/10.1007/s10787-006-1531-7)

This review examines the stable gastric pentadecapeptide BPC 157 (noted as safe in clinical trials for inflammatory bowel disease) and its cytoprotective activity in the context of the full, distended stomach and the vascular response. In an alcohol-instilled rat model, gastric, esophageal, and duodenal lesions develop alongside loss of left gastric artery vessel presentation; instillation of BPC 157 keeps vessel presentation constant and inhibits these stomach, esophagus, and duodenum lesions, whereas standard agents (atropine, ranitidine, omeprazole) only partially improve vessels and lesions. The authors emphasize BPC 157's unusual stability and its effects against various gastrointestinal lesions, on the nitric oxide system, somatosensory neurons, endothelium protection, endothelin, and angiogenesis promotion. They further note that, given peripherally, BPC 157 counteracts central dopamine-system disturbances and induces serotonin release in the substantia nigra, and that it can heal various wounds and instantly recover disturbed lower esophageal and pyloric sphincter pressure in rats with long-standing esophagitis.

### Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts

Chang CH, Tsai WC, et al. — *Molecules* (2014) — [PMID 25415472](https://pubmed.ncbi.nlm.nih.gov/25415472/) | [doi:10.3390/molecules191119066](https://doi.org/10.3390/molecules191119066)

This mechanistic study investigates the molecular pathways through which BPC-157 promotes tendon healing, specifically focusing on growth hormone receptor (GHR) expression in tendon fibroblasts isolated from the Achilles tendon of male Sprague-Dawley rats. Using cell culture models and molecular analysis techniques including cDNA microarray, RT/real-time PCR, and Western blotting, researchers demonstrated that BPC-157 treatment upregulates GHR expression in a dose- and time-dependent manner at both the mRNA and protein levels. The study reveals that BPC-157-induced GHR expression increases sensitivity to growth hormone signaling: adding growth hormone to BPC-157-treated fibroblasts dose- and time-dependently increased cell proliferation (MTT assay and PCNA) and activated the downstream Janus kinase 2 (JAK2) pathway. These findings provide mechanistic insight into how BPC-157 may potentiate growth hormone's proliferation-promoting effect and contribute to tendon repair, with implications for understanding tendinopathy and Achilles tendon injury recovery pathways.

### BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing

Seiwerth S, Rucman R, Turkovic B, et al. — *Current Pharmaceutical Design* (2018) — [PMID 29998800](https://pubmed.ncbi.nlm.nih.gov/29998800/) | [doi:10.2174/1381612824666180712110447](https://doi.org/10.2174/1381612824666180712110447)

This comparative study examines BPC-157's angiogenic properties alongside standard growth factors including VEGF (Vascular Endothelial Growth Factor) and bFGF (basic Fibroblast Growth Factor) in established wound healing models. The research demonstrates that BPC-157 promotes new blood vessel formation through distinct mechanisms while achieving comparable or superior results to traditional angiogenic factors. Microscopic analysis revealed increased capillary density, improved vessel maturation, and enhanced blood flow in BPC-157 treated wounds. The study documented accelerated wound closure rates, improved granulation tissue quality, and better cosmetic outcomes. Importantly, researchers found that BPC-157's angiogenic effects were achieved without the tumor-promoting concerns associated with some standard growth factors, suggesting a favorable safety profile for wound healing research applications.

### Stable gastric pentadecapeptide BPC 157 can improve the healing course of spinal cord injury and lead to functional recovery in rats

Perovic D, Kolenc D, Bilic V, et al. — *Journal of Orthopaedic Surgery and Research* (2019) — [PMID 31266512](https://pubmed.ncbi.nlm.nih.gov/31266512/) | [doi:10.1186/s13018-019-1242-6](https://doi.org/10.1186/s13018-019-1242-6)

This study investigated BPC-157's effects on spinal cord injury healing in a rat model. Researchers demonstrated that BPC-157 administration improved the healing course of spinal cord compression injury and promoted functional recovery. Treated animals showed significantly better neurological outcomes assessed by the BBB locomotor rating scale compared to controls. Histological analysis revealed reduced lesion size, decreased neuronal loss, and improved tissue preservation at the injury site. The study documented BPC-157's neuroprotective effects in the central nervous system, extending the peptide's documented tissue-protective properties beyond peripheral tissues to include spinal cord repair. These findings suggest BPC-157 may modulate neuroinflammation and promote neural tissue preservation through mechanisms consistent with its known cytoprotective activity in other tissue types.

### Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway

Hsieh MJ, Lee CH, Chueh HY, Chang GJ, Huang HY, Lin Y, Pang JHS — *Scientific Reports* (2020) — [PMID 33051481](https://pubmed.ncbi.nlm.nih.gov/33051481/) | [doi:10.1038/s41598-020-74022-y](https://doi.org/10.1038/s41598-020-74022-y)

This study demonstrates BPC-157's concentration-dependent vasodilation effect in isolated rat aorta through endothelium-dependent mechanisms. The research reveals that BPC-157 induces nitric oxide generation via activation of the Src-Caveolin-1-eNOS signaling pathway. Key findings include enhanced phosphorylation of Src, Caveolin-1, and eNOS, with the vasodilation effect being abolished by nitric oxide inhibitors. The study provides mechanistic insight into how BPC-157 modulates vascular tone and promotes endothelial cell migration, supporting its role in angiogenesis and cardiovascular protection.

### Stable Gastric Pentadecapeptide BPC 157 and Wound Healing

Seiwerth S, Milavic M, Vukojevic J, Gojkovic S, Krezic I, et al. — *Frontiers in Pharmacology* (2021) — [PMID 34267654](https://pubmed.ncbi.nlm.nih.gov/34267654/) | [doi:10.3389/fphar.2021.627533](https://doi.org/10.3389/fphar.2021.627533)

This comprehensive review examines BPC-157's wound healing capabilities across multiple tissue types including skin incisions, deep burns, diabetic ulcers, and alkali burns. The authors demonstrate that BPC-157 simultaneously heals cutaneous and internal wounds in various fistula models. The peptide's healing mechanism involves resolution of vessel constriction, platelet plug formation, and fibrin stabilization. Notably, BPC-157 counteracts both arterial and venous thrombosis while promoting vessel circumvention in ischemia-reperfusion scenarios. The review also documents rapid gene expression changes in skin wounds that parallel healing observed in gastrointestinal tract, tendon, ligament, muscle, bone, nerve, and blood vessels.

## Frequently Asked Questions

### What is BPC-157 and where does it come from?

BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide derived from a protective protein found in human gastric juice. It was first characterized by Professor Predrag Sikiric and colleagues at the University of Zagreb in the early 1990s. The peptide does not occur naturally in isolation—it is a specific sequence engineered for research stability and bioavailability.

### What makes BPC-157 unusual among research peptides?

BPC-157's most distinctive property is its exceptional stability in gastric acid and resistance to enzymatic degradation. This stability allows it to be administered orally in animal models and retain bioactivity—a property almost unique among research peptides. Most peptides are degraded rapidly in the gut, but BPC-157's sequence resists this breakdown, enabling meaningful gastrointestinal research protocols.

### What are the primary research applications for BPC-157?

The bulk of BPC-157 research has focused on tissue repair (tendon, muscle, ligament, bone), gastrointestinal protection (ulcer models, IBD models, gut-brain axis), wound healing acceleration, and neuroprotection. Secondary areas include cardiovascular protection and organ protection in toxicity models. All published evidence is from animal or in vitro studies—no peer-reviewed human clinical trials have been completed as of 2026.

### How does BPC-157 promote tissue repair?

The most studied mechanisms include: upregulation of growth hormone receptors in fibroblasts (increasing sensitivity to healing signals), activation of the FAK-paxillin pathway (promoting cell adhesion and migration), modulation of the nitric oxide system through Src-Caveolin-1-eNOS phosphorylation (enhancing vascular function), and dual activation of the Egr-1/NAB2 gene loop (promoting organized, non-chaotic blood vessel growth). The peptide does not work through a single receptor but rather through simultaneous modulation of multiple healing pathways.

### What is the 'Gene Expression Paradox' in BPC-157 research?

The Gene Expression Paradox refers to the observation that BPC-157 is cleared from systemic circulation in approximately 15 minutes (mean elimination half-life in rats), yet its reparative effects persist for weeks. Researchers propose that the peptide's brief presence is sufficient to trigger a cascade of gene expression changes—including activation of transcription factors c-Fos, c-Jun, and Egr-1—that initiate self-sustaining healing processes well beyond the peptide's physical presence.

### Can BPC-157 be taken orally and does it still work?

In animal models, yes. BPC-157 retains biological activity when administered orally via gavage in rodent studies, which is attributed to its remarkable stability in gastric juice. This property is well-documented in publications by Sikiric and colleagues. However, whether oral bioavailability translates meaningfully to humans has not been established in clinical trials. Animal gut anatomy and digestive physiology differ from humans, so caution is warranted in extrapolating these findings.

### What does BPC-157 research show for gastrointestinal conditions?

Animal studies have demonstrated BPC-157's cytoprotective effects against NSAID-induced gastric lesions, alcohol-induced stomach damage, stress ulcers, and models of inflammatory bowel disease (ulcerative colitis and Crohn's disease). The peptide appears to reduce mucosal inflammation, accelerate intestinal healing, and restore intestinal barrier function. Its gastric stability makes it particularly suited for GI research, though human clinical evidence is currently absent.

### Has BPC-157 been tested in humans?

As of early 2026, no peer-reviewed human clinical trials for BPC-157 have been published. The research base—though extensive, comprising over 100 published studies—is entirely preclinical (animal models and in vitro experiments). A Phase I safety study has been mentioned in some literature, but results have not been published. BPC-157 is not approved for human use by any regulatory agency.

### What is BPC-157's half-life?

In formal pharmacokinetic studies in rats following intravenous administration, BPC-157 has a mean elimination half-life of approximately 15.2 minutes, with the peptide becoming undetectable within 4 hours. This rapid clearance contrasts sharply with its prolonged biological effects, which is the basis of the Gene Expression Paradox. No human pharmacokinetic data has been published.

### How does BPC-157's angiogenesis compare to VEGF?

BPC-157 promotes angiogenesis through the Egr-1/NAB2 regulatory loop, which simultaneously activates vessel growth (Egr-1) and provides an internal brake (NAB2) to prevent disorganized growth. Standard angiogenic factors like VEGF primarily accelerate growth without this built-in regulatory mechanism. Research suggests BPC-157 can promote healing in the eye while opposing pathological vessel growth—a balance that VEGF alone does not provide. This organized approach may be why BPC-157 has been studied in sensitive anatomical areas.

### Is BPC-157 banned in competitive sports?

Yes. BPC-157 was added to the World Anti-Doping Agency (WADA) Prohibited List effective January 1, 2022, under category S0 (Non-Approved Substances). This classification prohibits its use by athletes both in and out of competition. WADA's rationale is that BPC-157 is a pharmacological substance not approved for human therapeutic use by any regulatory authority, and its tissue repair properties could provide a performance-enhancing benefit. Athletes subject to USADA, UKAD, or other WADA-signatory testing programs should be aware of this status.

### What is the difference between BPC-157 acetate and arginine salt forms?

BPC-157 acetate is the original research form — the peptide is paired with an acetate counterion during synthesis. BPC-157 arginine salt pairs the peptide with arginine, which acts as a stabilizing counterion that improves solubility and pH stability in solution. Both forms contain the identical 15-amino acid active peptide sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val). The arginine salt is generally preferred in research for its improved solution stability, particularly at physiological pH ranges.

## Related Peptides

- [TB-500](https://peptpedia.org/peptide/tb-500)
- [TB4-FRAG](https://peptpedia.org/peptide/tb4-frag)
- [GHK-Cu](https://peptpedia.org/peptide/ghk-cu)

---

This content is for educational and research purposes only. It is not medical advice, and the compounds covered are research chemicals not approved for human use unless explicitly stated otherwise.

Cite this page: Peptpedia — Research Peptide Encyclopedia, https://peptpedia.org